Download PDF
Methods Inf Med 2004; 43(01): 83-88
DOI: 10.1055/s-0038-1633841
Original Article
Schattauer GmbH

EuCliD® – A Medical Registry

H. Steil
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
C. Amato
2   Fresenius Medical Care Southern Europe, IT Department, Vaiano, Italy
,
C. Carioni
2   Fresenius Medical Care Southern Europe, IT Department, Vaiano, Italy
,
J. Kirchgessner
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
D. Marcelli
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
A. Mitteregger
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
V. Moscardo
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
G. Orlandini
1   Fresenius Medical Care, Department CME, Bad Homburg, Germany
,
E. Gatti
3   Fresenius Medical Care, Member of the Board, Bad Homburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
07 February 2018 (online)

    Permissions and Reprints

Summary

Objectives: The European Clinical Database EuCliD® [*] has been developed as a tool for supervising selected quality indicators of about 200 European dialysis centers. Major efforts had to be made to comply with local and European laws regarding data security.

Method: EuCliD® is a Lotus Notes® based flat-file database currently containing medical data of more than 14,000 dialysis patients from 10 European countries. Another 15,000 patients from 150 centers in 4 South-American countries will be added soon. Data are entered either manually or by means of interfaces to existing local data managing systems. This information is transferred to a central Lotus Notes Server. Data evaluation was performed with statistical tools like SPSS.

Results: EuCliD® is used as a part of the CQI (Continuous Quality Improvement) management system of Fresenius Medical Care (FMC) dialysis units. Each participating dialysis center receives (currently every half year) benchmarking reports at a regular interval. The benchmark for all quality parameters is the weighted mean of the corresponding data of all centers.

Conclusions: An obvious impact of data sampling and data evaluation on the quality of the treatments could be observed within the first one and a half years of working with EuCliD®. This also concerns important outcome predictors like Kt/V and hemoglobin concentration as the outcome itself expressed in hospitalization days and survival rates. With the help of EuCliD® the user is able to sample clinical data, identify problems, search for solutions with the aim of improving the dialysis treatment quality and guarantee a high-class treatment quality for all patients.

Keywords

Medical registry - clinical database - Lotus Notes - Continuous Quality Improvement

* EuCliD® is a Trademark of Fresenius Medical Care Deutschland GmbH, finally registered in Germany, provisionally registered in all (Western and Eastern) European countries.


 

  • References

  • 1 NKF-DOQI Clinical Practice Guidelines for haemodialysis adequacy. New York: National Kidney Foundation; 1997
    Search in Google Scholar
  • 2 European best practice guidelines for the management of anemia in patients with chronic renal failure. NDT 1999; 14 suppl 5
    PubMedSearch in Google Scholar
  • 3 The Renal Association. Treatment of adult patients with renal failure: recommended standards and audit measures (2nd Edition).
    PubMed
  • 4 1997 Gruppi di lavoro delle linee guida SIN. Linee guida della Società italiana di Nefrologia. www.sin-italia.org/protocol/
    PubMed
  • 5 Hays RD, Sherborne CD, Mazel RM. The RAND 36-Item Health Survey1.0. Health Econ 1993; 2: 217-27.
    CrossrefPubMedSearch in Google Scholar